仿¥ã®åé¡ï¼ãè¥ã女æ§ã®åç´ãªèè±çã ãèµ·çèã¯ESBLç£çã®å¤§è
¸èã
æåæ§ï¼
èæ§ï¼nitrofurantoin, levofloxacin, and trimethoprim--sulfamethoxazole
ä¸éï¼Amoxicillin-Clavulanate
ææ§ï¼cefepime, gentamicin, piperacilin-tazobactam, and imipenem
ä¸è¨ã®ã©ããé¸ã¶ãï¼ï¼
å ¥é¢ãã¦3æ¥éã®MeropenemãCefepimeã夿¥ã§7æ¥éã®Ertapenemãä¸çºGentamicin.
æ£è§£ï¼
夿¥ã§Gentamicinä¸çº
ï¼æ¥æ¬ã«Nitrofurantoinç¡ããEratpenemç¡ããæ¥æ¬ã«ããããCefepime,ãPIPC/TAZè«å¤ãMeropenemãã£ãããªãï¼
åèï¼
IDSA 2024 Guidance on the Treatment of Antimicrobial Resistant Gram-Negative Infections
https://www.idsociety.org/practice-guideline/amr-guidance/
ã¤ãã«èè±çã«ã¢ããã°ãªã³ã·ãã®æä»£ãã»ã»
æ®ã©æ¯å¹´ã®ããã«èæ§GNRã®ã¬ã¤ãã©ã¤ã³ãåºãæä»£ãã»ã»
ç·¨éé·ï¼
ååã¯èªç¶ã«æ²»ãåç´ãªèè±çãâãæ°´ã®ãã§å®éãè¯ãããã»ã»ï¼ç¬ï¼
æåæ§ï¼
èæ§ï¼nitrofurantoin, levofloxacin, and trimethoprim--sulfamethoxazole
ä¸éï¼Amoxicillin-Clavulanate
ææ§ï¼cefepime, gentamicin, piperacilin-tazobactam, and imipenem
ä¸è¨ã®ã©ããé¸ã¶ãï¼ï¼
å ¥é¢ãã¦3æ¥éã®MeropenemãCefepimeã夿¥ã§7æ¥éã®Ertapenemãä¸çºGentamicin.
æ£è§£ï¼
夿¥ã§Gentamicinä¸çº
ï¼æ¥æ¬ã«Nitrofurantoinç¡ããEratpenemç¡ããæ¥æ¬ã«ããããCefepime,ãPIPC/TAZè«å¤ãMeropenemãã£ãããªãï¼
åèï¼
IDSA 2024 Guidance on the Treatment of Antimicrobial Resistant Gram-Negative Infections
https://www.idsociety.org/practice-guideline/amr-guidance/
ã¤ãã«èè±çã«ã¢ããã°ãªã³ã·ãã®æä»£ãã»ã»
æ®ã©æ¯å¹´ã®ããã«èæ§GNRã®ã¬ã¤ãã©ã¤ã³ãåºãæä»£ãã»ã»
ç·¨éé·ï¼
ååã¯èªç¶ã«æ²»ãåç´ãªèè±çãâãæ°´ã®ãã§å®éãè¯ãããã»ã»ï¼ç¬ï¼